Myron John Tong

Summary

Affiliation: Huntington Medical Research Institutes
Country: USA

Publications

  1. doi request reprint Hepatitis B inactive carriers: clinical course and outcomes
    Myron J Tong
    Liver Center, Huntington Medical Research Institutes, Pasadena, California 91105, USA
    J Dig Dis 14:311-7. 2013
  2. doi request reprint The management of chronic hepatitis B in Asian Americans
    Myron J Tong
    Pfleger Liver Institute, Division of Digestive Diseases, University of California School of Medicine, Los Angeles, CA, USA
    Dig Dis Sci 56:3143-62. 2011
  3. doi request reprint Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update
    Myron John Tong
    Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    J Gastroenterol Hepatol 26:829-35. 2011
  4. doi request reprint Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic
    Myron J Tong
    The Liver Center, Huntington Medical Research Institutes, Pasadena, CA 91105, USA
    Dig Dis Sci 55:826-35. 2010
  5. doi request reprint Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA
    Myron J Tong
    The Dumont UCLA Liver Cancer Center, Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    J Clin Gastroenterol 44:e63-70. 2010
  6. doi request reprint Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen
    Myron John Tong
    The Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 7:889-93. 2009
  7. doi request reprint Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis
    Myron John Tong
    The Pfleger Liver Institute, Division of Digestive Diseases, David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA, USA
    Dig Dis Sci 54:1337-46. 2009
  8. doi request reprint Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States
    Myron John Tong
    The Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine at the University of California in Los Angeles, CA, USA
    Hepatology 48:1070-8. 2008
  9. pmc Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers
    Myron J Tong
    The Liver Center, Huntington Medical Research Institutes, Pasadena, CA 91105, USA
    Liver Int 27:1356-63. 2007
  10. ncbi request reprint Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma
    Myron J Tong
    Liver Center, Huntington Medical Research Institutes, 660 South Fair Oaks Avenue, Pasadena, California 91105, United States
    World J Gastroenterol 12:6620-6. 2006

Detail Information

Publications11

  1. doi request reprint Hepatitis B inactive carriers: clinical course and outcomes
    Myron J Tong
    Liver Center, Huntington Medical Research Institutes, Pasadena, California 91105, USA
    J Dig Dis 14:311-7. 2013
    ..We aimed to determine the clinical impact of ALT and HBV DNA elevations during the course of HBV infection...
  2. doi request reprint The management of chronic hepatitis B in Asian Americans
    Myron J Tong
    Pfleger Liver Institute, Division of Digestive Diseases, University of California School of Medicine, Los Angeles, CA, USA
    Dig Dis Sci 56:3143-62. 2011
    ..These recommendations are based on a review of relevant literature and the opinion of a panel of Asian American physicians with expertise in hepatitis B treatment...
  3. doi request reprint Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update
    Myron John Tong
    Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    J Gastroenterol Hepatol 26:829-35. 2011
    ..We sought to determine whether these guidelines identified patients who developed hepatocellular carcinoma (HCC) or who died of non-HCC liver-related deaths for antiviral therapy...
  4. doi request reprint Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic
    Myron J Tong
    The Liver Center, Huntington Medical Research Institutes, Pasadena, CA 91105, USA
    Dig Dis Sci 55:826-35. 2010
    ..HCC patients often present with poor liver function and large tumors resulting in rapid mortality. The impact of HCC surveillance and subsequent therapy on patient survival remain controversial...
  5. doi request reprint Survival in Asian Americans after treatments for hepatocellular carcinoma: a seven-year experience at UCLA
    Myron J Tong
    The Dumont UCLA Liver Cancer Center, Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    J Clin Gastroenterol 44:e63-70. 2010
    ..The aims of this study were to examine the tumor characteristics and liver disease status in HCC patients of Asian ancestry and determine their survival after treatments for HCC...
  6. doi request reprint Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen
    Myron John Tong
    The Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 7:889-93. 2009
    ..However, the long-term clinical outcomes of this process are not well established...
  7. doi request reprint Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis
    Myron John Tong
    The Pfleger Liver Institute, Division of Digestive Diseases, David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA, USA
    Dig Dis Sci 54:1337-46. 2009
    ..Hepatitis B viral markers and liver tests were used as predictors for development of hepatocellular carcinoma and progression to end-stage liver disease in 128 cirrhosis patients with hepatitis B...
  8. doi request reprint Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States
    Myron John Tong
    The Pfleger Liver Institute and the Division of Digestive Diseases, David Geffen School of Medicine at the University of California in Los Angeles, CA, USA
    Hepatology 48:1070-8. 2008
    ..In addition, if basal core promoter T1762/A1764 mutants and precore A1896 mutants also were included, then 100% of patients who developed HCC would have been identified for treatment...
  9. pmc Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers
    Myron J Tong
    The Liver Center, Huntington Medical Research Institutes, Pasadena, CA 91105, USA
    Liver Int 27:1356-63. 2007
    ..However, the differences in these viral factors in chronic carriers who seldom develop HCC compared with HCC patients have not been adequately evaluated...
  10. ncbi request reprint Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma
    Myron J Tong
    Liver Center, Huntington Medical Research Institutes, 660 South Fair Oaks Avenue, Pasadena, California 91105, United States
    World J Gastroenterol 12:6620-6. 2006
    ..To conduct a retrospective study in 400 chronic hepatitis B patients in order to identify hepatitis B viral factors associated with complications of liver disease or development of hepatocellular carcinoma...
  11. ncbi request reprint Treatment of patients with chronic hepatitis B with adefovir dipivoxil
    Myron J Tong
    Liver Center, Huntington Medical Research Institutes, Pasadena, California 91105, USA
    Semin Liver Dis 24:37-44. 2004
    ..No major drug-related side effects were noted. Adefovir 10 mg/d orally is safe and effective for treatment of chronic hepatitis B...